How Ozempic Is Quietly Reshaping the US Restaurant Business

The GLP-1 category — what actually got FDA-approved, when, at what scale

Semaglutide (Novo Nordisk). Ozempic (subcutaneous injection) approved by the US FDA in December 2017 for improved glycemic control in adults with type 2 diabetes. Rybelsus (oral semaglutide) approved September 2019. Wegovy (higher-dose subcutaneous semaglutide) approved June 2021 specifically for chronic weight management in adults with obesity or overweight with at least one weight-related condition. Ozempic and Wegovy contain the same active ingredient at different doses.

Tirzepatide (Eli Lilly). Mounjaro approved May 2022 for type 2 diabetes. Zepbound approved November 2023 for chronic weight management. Tirzepatide is a dual GIP/GLP-1 receptor agonist — mechanistically distinct from semaglutide and, in head-to-head trials, showing greater weight loss on average.

Older-generation GLP-1s. Liraglutide (Novo Nordisk's Victoza for diabetes, Saxenda for weight management), dulaglutide (Eli Lilly's Trulicity), exenatide (Byetta, Bydureon). Smaller share than the semaglutide/tirzepatide generation.

Pipeline. Novo Nordisk has additional programs (CagriSema combining semaglutide + cagrilintide; oral semaglutide 25 mg and 50 mg for weight). Eli Lilly has retatrutide (triple agonist), orforglipron (oral small-molecule GLP-1) in late-stage trials. Amgen, Pfizer, Roche, Structure Therapeutics, Viking Therapeutics have programs. Compounded semaglutide peptides via 503A/503B pharmacies became a US phenomenon in 2022-2024, with FDA warning letters and legal action; the FDA removed semaglutide from the drug shortage list in October 2024 (effective February 2025 for the compounding shift), restricting large-scale compounding.

Scale. Novo Nordisk's public quarterly earnings, and Eli Lilly's, both show GLP-1 franchises among the top revenue-generating pharmaceutical categories globally. IQVIA prescription-tracking data (referenced by industry and financial-analyst coverage) points to millions of US adults with a GLP-1 prescription across the category. Insurance coverage varies materially — Medicare generally does not cover weight-loss drugs (though CMS has signalled review), Medicaid coverage varies by state, commercial insurance coverage is inconsistent (Wegovy and Zepbound often excluded or subject to prior authorisation). Cash-pay at list price ($900-1,300/month) or at manufacturer-supported reduced cash-pay programs (Eli Lilly LillyDirect self-pay Zepbound single-dose vials at reduced pricing announced 2024).

The biological mechanism relevant to restaurants

GLP-1 receptor agonism. GLP-1 (glucagon-like peptide-1) is a natural incretin hormone released from intestinal L-cells post-meal. It stimulates glucose-dependent insulin secretion, suppresses glucagon, slows gastric emptying, and acts on hypothalamic satiety centres to reduce appetite. Semaglutide and tirzepatide are pharmacologic agonists — they bind and activate the same receptors, but with much longer half-lives (once-weekly dosing) and higher potency than endogenous GLP-1.

Clinical trial evidence. The STEP trial programme (semaglutide 2.4 mg weekly for weight management) published in the New England Journal of Medicine and JAMA showed average weight loss on the order of ~15% over 68 weeks in adults with obesity (STEP 1, 2021), with sustained effect at higher-quality endpoints. The SURMOUNT trial programme (tirzepatide for weight management) showed average weight loss on the order of ~15-22% at maximal doses over 72 weeks. SELECT trial (semaglutide, NEJM 2023) showed a cardiovascular event reduction in patients with established cardiovascular disease and overweight/obesity — a landmark finding that repositioned semaglutide beyond weight loss into cardiometabolic prevention.

Appetite and eating behaviour changes. Peer-reviewed studies and patient-reported outcomes consistently document: (a) reduced overall caloric intake; (b) reduced portion size per meal; (c) reduced snacking between meals; (d) reduced 'hedonic' eating (eating for pleasure rather than hunger — a real neuroscience literature emerging on GLP-1 effects on brain reward circuitry, published in Nature Medicine and Cell Metabolism); (e) taste changes and food aversions in some patients (especially early in treatment); (f) reduced alcohol consumption in a subset (early observational studies + emerging trial data on GLP-1s and alcohol use disorder — small-scale Randomised Controlled Trials showed effect in reducing heavy drinking).

Side effects and adherence. GI side effects (nausea, vomiting, constipation, diarrhoea) are common especially during dose titration. Discontinuation rates in clinical practice higher than in trials — a substantial fraction of patients discontinue within 12 months, particularly if paying cash and if benefit plateaus. Weight regain post-discontinuation is documented (STEP 1 extension, JAMA 2022 — patients regained approximately two-thirds of lost weight in year following discontinuation). This affects the restaurant impact modelling — the population currently on therapy at any point in time is a moving target.

What restaurant industry data and operator commentary have shown so far

Morgan Stanley 2023 consumer survey. Widely-cited Morgan Stanley consumer research published in 2023 pointed to reduced restaurant visits and reduced spending on 'indulgent' food categories among consumers on GLP-1 therapy vs. comparable non-users. The survey noted particular pull-back in fast food, salty snacks, and sugary beverages.

Cornell Institute for Healthy Futures / restaurant industry analysis. Cornell's hospitality faculty and the restaurant industry research community have published commentary flagging the category-level implications — especially for high-portion casual dining and dessert-attach fast food.

National Restaurant Association. The NRA's periodic 'State of the Industry' reports have referenced the GLP-1 shift among broader macro headwinds (inflation, labour, consumer spending softness).

Public company earnings commentary. Selected examples from public restaurant-company earnings calls and investor presentations 2023-2024 (readers should consult specific quarterly transcripts for verbatim statements):

• Bloomin' Brands (Outback Steakhouse, Bonefish Grill, Carrabba's, Fleming's) — leadership has publicly acknowledged monitoring GLP-1 impact on portion consumption and check sizes; the company operates in the alcohol-forward, larger-portion casual-dining category where the exposure profile is arguably highest.
• Darden Restaurants (Olive Garden, LongHorn, Yard House, Ruth's Chris) — Darden management has been asked about GLP-1 impact on multiple earnings calls; consistent framing has been that impact is measurable but modest at current adoption levels.
• Cheesecake Factory — high-portion dessert-forward positioning, monitored.
• Denny's, IHOP (Dine Brands), Applebee's — family diner category with dessert attach.
• Shake Shack, Wingstop, Wendy's, McDonald's, Chipotle Mexican Grill — fast food and fast-casual leaders have referenced GLP-1 in varied framing.
• Starbucks, Dunkin' Brands (Inspire Brands) — beverage-and-dessert-forward category monitored.
• Krispy Kreme, Dutch Bros Coffee — indulgence-forward categories.

Adjacent category signals. Grocery-store snack-aisle sales data (Nielsen IQ, Circana) has shown category softness in snacks and salty snacks pockets that some analysts have attributed in part to GLP-1 uptake. Alcohol off-premise sales softness likewise partially attributed. Ready-to-eat prepared meals and higher-protein food categories have shown relative strength.

Caveats. Attribution is hard. The 2022-2025 US consumer spending environment also included high inflation, labour cost passthroughs, shifting delivery-vs-dine-in mix post-pandemic, higher interest rates, and reduced discretionary spending among lower-income households — all of which can produce similar-looking soft-spot dynamics. GLP-1 is one factor among several. Rigorous causal attribution would require difference-in-differences studies with real prescription-linked consumer panel data — not yet widely published.

Which restaurant categories carry more exposure — the framework

Higher-exposure characteristics.

• High-portion positioning. Buffet, all-you-can-eat, large-portion casual dining (Cheesecake Factory 'huge portions' brand promise, Old Country Buffet-style concepts).
• Dessert-forward or dessert-attach dependent. Cheesecake Factory, IHOP, Denny's, Applebee's, Dunkin', Krispy Kreme, Cinnabon, Baskin-Robbins.
• Alcohol-forward casual. Bloomin' Brands' Outback/Bonefish/Carrabba's, Darden's Olive Garden/LongHorn/Yard House, BJ's Restaurant, Buffalo Wild Wings (bar-forward), Chili's.
• Beverage-forward with high-sugar SKU. Starbucks Frappuccino, Dutch Bros sugar drinks, McDonald's McCafé milkshakes, Sonic slushes.
• Snack and impulse-buy category. Convenience-store food service, gas-station food-court, movie theatre concessions.

Lower-exposure characteristics.

• Value-oriented low-portion. Chipotle Mexican Grill bowl format, Panera Bread bakery-café, Sweetgreen salad bowl, CAVA Mediterranean bowl — inherent portion control + GLP-1-user-friendly compositions.
• Protein-forward. Steakhouse premium (Morton's, Ruth's Chris, STK Steakhouse) — GLP-1 users often continue eating protein even at reduced portion; smaller check but still visit.
• Fresh-produce-heavy grocery-adjacent prepared foods. Whole Foods, Sprouts, Trader Joe's prepared meals.
• Tasting-menu and small-plate concepts. Fine dining, izakaya, tapas — small-portion positioning already aligned with GLP-1 user preferences.
• Coffee shops without dessert dependence. Independent third-wave coffee shops focused on beans + minimal food attach.
• Health-forward positioning. Smoothie bowls, açaí, juice bar concepts.

Adaptation moves being observed.

(a) Smaller-portion menu additions with prominent labelling.
(b) Higher-protein-per-calorie menu redesigns.
(c) Beverage mix rebalancing — sparkling water and zero-sugar options prominence.
(d) Loyalty-programme adjustments — visit-frequency-based rewards rather than spend-per-visit.
(e) Off-premise + delivery focus (GLP-1 users still order, but smaller).
(f) Catering and group-occasion push (individual portion decline hits, but corporate catering and events remain).

The macro numbers to actually track

Public data streams a restaurant operator can watch:

• Novo Nordisk quarterly earnings (novonordisk.com/investors) — Wegovy + Ozempic volume; obesity segment revenue trajectory; guidance revisions.
• Eli Lilly quarterly earnings (investor.lilly.com) — Mounjaro + Zepbound volume; obesity segment revenue.
• IQVIA / Trilliant Health reports — prescription volume; new-start vs continuing-patient mix; adherence rates.
• National Restaurant Association 'State of the Industry' annual reports — category revenue trajectory, price/traffic mix, category shifts.
• Cornell School of Hotel Administration research — hospitality-industry-focused academic analysis.
• Bureau of Labor Statistics Consumer Expenditure Survey — food-away-from-home spending by demographic slice.
• Nielsen IQ + Circana (formerly IRI + NPD Group merger) point-of-sale and consumer-panel data — packaged snack, alcohol, prepared food category tracking.
• Publicly-traded restaurant company quarterly earnings transcripts — verbatim operator commentary on same-store sales trends, check size, portion adjustments.
• CMS coverage decisions — Medicare weight-loss drug coverage; state Medicaid coverage changes; commercial insurance coverage expansion — each of these would step-change adoption.
• Peer-reviewed clinical literature — long-term outcome data (5-year, 10-year); real-world discontinuation and regain patterns.

Emerging watch items.

• Compounded semaglutide/tirzepatide shift post-October 2024 FDA shortage delisting (effective February 2025 for the semaglutide compounding restrictions) — lower-cost supply route is materially narrower going forward. Effect: could reduce total-adherent-users count in the near term if commercial insurance coverage does not expand to cover the price gap.
• Oral semaglutide 25 mg / 50 mg for weight — if approved, changes the delivery experience (oral daily vs. weekly injection) and could expand accessible-user pool.
• Second-generation GLP-1s — CagriSema, orforglipron, retatrutide in late-stage trials; higher-efficacy or lower-side-effect profiles could accelerate adoption.
• Medicare Part D coverage decision on weight-loss drugs — currently excluded under the statute; policy change would materially expand the covered US population over 65.
• Real-world 5-year outcome data — cardiovascular, renal, cognitive outcome trials (SELECT, FLOW, EVOKE) reading out could position GLP-1s beyond weight loss into broad cardiometabolic prevention — expanding the prescribed population.

For restaurant operators — practical framing

GLP-1 adoption is real, measurable, and durable — probably not a fad but a structural adjustment. The category effect on restaurants is real but currently modest at aggregate levels; it stacks with other headwinds (inflation, labour, post-pandemic delivery mix, macro consumer spending). No single operator quarter is 'the Ozempic quarter'; the signal builds over years.

What an independent restaurant operator can do right now:

(1) Track check-size trend at the item level. If dessert-attach rate on 12-month rolling data is trending down among repeat customers, that's a signal worth noting.

(2) Add small-portion menu options. Not just 'small' — explicitly positioned as protein-forward, portion-aware. Loyalty-visit-friendly.

(3) Rebalance beverage mix. Sparkling water, zero-sugar, low-alcohol / no-alcohol cocktails ('mocktails'), premium hot beverage options — margins can be strong on these SKUs.

(4) Loyalty programme adjustment. Reward frequency and repeat visit, not average ticket size. GLP-1 users may keep visiting at similar frequency but at lower ticket — rewarding the visit pattern preserves the customer.

(5) Off-premise and catering. Catering demand is less exposed than individual dine-in — corporate lunches, events, family gatherings maintain aggregate order size.

(6) Menu R&D discipline. New menu-item development with an explicit GLP-1-user usability screen — could this item work for someone whose gastric emptying is slowed? Portion, digestibility, spice, fat content, protein density all matter.

(7) Communication. Some operators are marketing GLP-1-friendly menu options explicitly (small-portion tasting menus, protein-forward bowls) — early experimentation, read the customer response before committing category.

For restaurant industry investors and observers, the framing to hold: this is a category headwind on the order of magnitude of a persistent 1-3% negative same-store-traffic drag for exposed categories, layered on top of other pressures — not a step-change collapse, but a real adjustment that concentrates in specific format archetypes. It rewards portfolio positioning (chains with format diversity across value/casual/fine-dining) over concentrated high-exposure pure-plays.

The bigger frame — this is a decades-long adjustment, not a quarter-to-quarter shock

GLP-1 drugs and their successors mark a structural change in how food demand is generated. The obesity-treatment market is projected by major banking analysts (Morgan Stanley, JPMorgan, Goldman Sachs, Barclays healthcare) to reach the tens of billions or hundred+ billion USD scale over the next 5-10 years, driven by expanded insurance coverage, lower-cost supply, oral formulations, and second-generation compounds with better efficacy/side-effect profiles.

For the restaurant industry, this is a slower version of what tobacco and alcohol regulation did to their respective categories — a gradual, decades-long behavioural adjustment that penalises certain format archetypes and rewards others.

Format winners are likely to be: protein-forward concepts; small-portion tasting menu; fresh-produce-heavy prepared meals; beverage-first with low-sugar depth; catering + group-occasion; loyalty-frequency-rewarded concepts.

Format losers are likely to be: buffet and all-you-can-eat; dessert-attach-dependent fast food; sugary beverage-reliant chains without diversification; alcohol-heavy casual dining without menu evolution.

The middle is where most operators sit — and the quality of adaptation over the next 5-10 years will separate winners from strugglers within the middle. Real menu R&D, real portion architecture, real beverage program reinvention, real loyalty programme design. Not marketing spin.

A note on data integrity. The best restaurant operators will build the tracking infrastructure now — item-level check composition trending, dessert-attach cohort tracking, beverage mix by daypart, catering vs. individual mix — so that when the aggregate signal grows stronger over the next 3-5 years, they see it clearly in their own numbers rather than reading it in industry press.